Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy

Health Expectations

Volumn 17, Issue 6, 2014, Pages 809-817

  Wang, Karen K W ^a   Charles, Cathy ^a   Heddle, Nancy M ^a,b   Arnold, Emmy ^a   Molnar, Laura ^a   Arnold, Donald M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Patient preferences; Thrombocytopenia; Treatment decision making

Indexed keywords

ADULT; CANADA; FEMALE; HUMAN; INTERVIEW; MIDDLE AGED; PATIENT ATTITUDE; PATIENT PREFERENCE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITATIVE RESEARCH; SPLENECTOMY; STATISTICS AND NUMERICAL DATA;

ADULT; CANADA; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PREFERENCE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITATIVE RESEARCH; SPLENECTOMY;

EID: 84911945652     PISSN: 13696513     EISSN: 13697625     Source Type: Journal    
DOI: 10.1111/j.1369-7625.2012.00806.x     Document Type: Article

References (26)

1. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 2011; 117: 4190-4207.
2. Stasi R, Newland A, Thornton P, Pabinger I. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Annals of Hematology, 2010; 89: 1185-1195.
3. Rodeghiero F, Ruggeri M. Is splenectomy still the gold standard for the treatment of chronic ITP? American Journal of Hematology, 2008; 83: 91.
4. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 2004; 104: 2623-2634.
5. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. Journal of Infection, 2001; 43: 182-186.
6. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Jacobsen J, Fryzek JP, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Annals of Internal Medicine, 2009; 151: 546-555.
7. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine, 2007; 146: 25-33.
8. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. New England Journal of Medicine, 2011; 365: 734-741.
9. Aleem A, Alaskar AS, Algahtani F, Rather M, Almahayni MH, Al-Momen A. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients. International Journal of Hematology, 2010; 92: 283-288.
10. Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. European Journal of Haematology, 2008; 81: 165-169.
11. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs, 2008; 68: 901-912.
12. Sandelowski M. Whatever happened to qualitative description? Research in Nursing & Health, 2000; 23: 334-340.
13. Sandelowski M. What's in a name? Qualitative description revisited. Research in Nursing & Health, 2010; 33: 77-84.
14. Patton M. Qualitative Research and Evaluation Methods, 3rd edn. Newbury Park: Sage Publications, 2002.
15. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009; 113: 2386-2393.
16. Sandelowski M. Sample size in qualitative research. Research in Nursing & Health, 1995; 18: 179-183.
17. Elwyn G, O'Connor AM, Bennett C, Newcombe RG, Politi M, Durand MA, et al. Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi). PLoS One, 2009; 4: e4705.
18. Charles C, Redko C, Gafni A, Whelan T, Reyno L. Doing nothing is no choice: lay constructions of treatment decision-making among women with early-stage breast cancer. Journal of Sociology and Health, 1998; 20: 71-95.
19. Charles C, Gafni A, Whelan T, O'Brien MA. Treatment decision aids: conceptual issues and future directions. Health Expectations, 2005; 8: 114-125.
20. Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. Journal of the American Medical Association, 2004; 291: 2359-2366.
21. Charles C, Gafney A, Whelan T. Decision making in the physician-patient encounter: revisiting the shared treatment decision-making model. Social Science & Medicine, 1999; 49: 651-661.
22. Butow P, Harrison JD, Choy ET, Young JM, Spillane A, Evans A. Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan. Cancer, 2007; 110: 1937-1944.
23. Gibson J. Use of qualitative research to analyze patient and clinician decision making in carotid endarterectomy. Journal of Vascular Nursing, 2002; 20: 60-65.
24. Hudak PL, Clark JP, Hawker GA, Coyte PC, Mahomed NN, Kreder HJ, et al. "You're perfect for the procedure! Why don't you want it?" Elderly arthritis patients' unwillingness to consider total joint arthroplasty surgery: a qualitative study. Medical Decision Making, 2002; 22: 272-278.
25. Fulford KW. Bringing together values-based and evidence-based medicine: UK Department of Health Initiatives in the 'Personalization' of Care. Journal of Evaluation in Clinical Practice, 2011; 17: 341-343.
26. Neunert CE, Bright BC, Buchanan GR. Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Pediatric Blood & Cancer, 2008; 51: 513-516.